Nootropics Index - Save on smarter supplements
Nootropics>Fatty acids, lipids & phospholipids>Policosanol
Fatty acids, lipids & phospholipids

Policosanol

Policosanol (long-chain aliphatic alcohol mixture)

Policosanol is a mixture of long-chain wax alcohols studied mainly for blood-lipid markers. Results are mixed, and the cited human studies do not establish a focus or memory benefit. Compare the wax source, total policosanol per serving and alcohol profile; octacosanol is only one constituent. Check medication compatibility before adding it to a stack.

Food DerivedClinical ResearchLimited Human EvidenceMixed EvidenceForm Dependent EvidencePregnancy CautionLactation Caution
Updated October 2026/7 min read/9 citations
Reviewed by the NootropicsIndex editorial team.Method: prioritize cited human research and official safety or regulatory sources; compare retailer-listed prices without endorsing products.Affiliate disclosure
Extra caution

Who should avoid this or get expert review first

This is not a recommendation to use. These groups should treat the profile as a reason to slow down and verify safety, rules, and personal context.

  • People using aspirin or other blood-thinning medicines7Get prescriber or pharmacist review before combining policosanol with these medicines. In a seven-day trial, aspirin plus policosanol increased some platelet effects and one participant reported mild gum bleeding. Caution with other blood thinners is a precautionary extension, not a proven interaction with every drug.
  • Pregnancy, breastfeeding and children9The adult studies cited here do not establish safety for these groups. NIH advises caution with supplements beyond standard prenatal products during pregnancy or nursing, and professional guidance before giving supplements to children. This is a precaution, not evidence of a specific reproductive toxicity.
01

What is it?

What is policosanol?

6

Policosanol contains several long-chain alcohols extracted from waxes. The sugarcane mixture assessed by EFSA contained mostly octacosanol, plus triacontanol, hexacosanol and other alcohols. Composition depends on the source; a name alone does not establish an equivalent mixture.

What the evidence can answer2
The useful question is whether a defined mixture changes measured blood-lipid markers. Those findings do not by themselves demonstrate better concentration or memory.
02

Names, aliases and forms

Common Namespolicosanol; long-chain aliphatic alcohols; sugarcane-derived policosanol
03

Potential effects and evidence map

Grade C reflects mixed human lipid-marker findings, not established cognitive enhancement. A 2018 meta-analysis pooled favorable results but found substantial inconsistency. Two 2006 trials were negative; a 2023 Japanese trial reported favorable markers. These studies do not establish better focus, memory or long-term brain protection.

Effect domainMagnitudeGrade
Focus / attention2
UnknownConfidence: Medium

A focus benefit is not established by the cited human lipid studies.

Note A score of zero denotes no supported focus signal here; it is not proof that every possible effect has been excluded.

0/5
E
Memory / learning8
UnknownConfidence: Medium

A human memory or learning benefit is not established.

Note Blood-lipid measurements do not demonstrate cognitive improvement.

0/5
E
Cellular / long-term brain support3
UnknownConfidence: Low

Mixed lipid-marker findings are indirect evidence and do not establish long-term brain support.

Note Grade C describes the human lipid evidence; the zero score avoids assigning a brain benefit from those markers.

0/5
C
04

Typical dosages and timing

Typical
10-20 mg/day
Not a recommendation
Lower bound
10 mg
Profile value
Upper bound
20 mg
Profile value
Usual study doses110-20 mg/day

The German lipid trial described these as usual doses. Its higher-dose arms also tested 40 and 80 mg daily for 12 weeks without a dose-response advantage. These research amounts do not establish a nootropic regimen.

US trial amount220 mg/day

The US trial enrolled 40 otherwise healthy adults with mildly elevated cholesterol and used 20 mg daily for eight weeks. Lipid and inflammatory markers did not improve significantly versus placebo. The featured window is an observation period, not a promised onset or a recommended cycle.

05

Timing & effect horizon

Effect horizonUnknown
Unknown
US lipid-trial window2Cumulative
8 weeks
No established acute timing2

The cited human studies assess repeated use and blood markers. They do not establish an acute cognitive onset, a duration of felt effects or a human The time for blood levels to fall by half during the final elimination phase.Source for the complete mixture. Timing claims about an isolated constituent or animals cannot fill those gaps.

06

Safety, side effects and risk profile

GI discomfort1
Confidence: Medium

Digestive complaints were reported in a trial, without an excess over placebo.

Note Gastritis was among reported events in the 12-week German study; causation and an ingredient-specific rate were not established.

1/5
C
Interaction risk7
Confidence: Medium

Platelet effects warrant review before combining with aspirin or other blood-thinning medicines.

Note A small aspirin-combination trial supports a possible additive effect. It does not quantify major bleeding or prove an interaction with every anticoagulant.

2/5
C
What the minimal-risk rating covers2

The eight-week US study reported good tolerability and no significant adverse events. The minimal base rating applies to short-term oral use around the studied range in generally healthy adults. It does not establish long-term safety or cover interacting medicines, pregnancy or breastfeeding.

07

Interactions and cautions

Platelet findings need context4

A 30-day study found reduced platelet aggregation at both tested doses. This laboratory response supports a medication caution; it does not demonstrate fewer cardiovascular events or quantify the likelihood of clinical bleeding.

Before a procedure9

Tell the clinical team about policosanol and other supplements before a planned procedure. Let that team determine whether any change is needed; the cited studies do not establish a policosanol-specific stop interval.

08

Legal and regulatory status

United States — checked 14 October 20265

FDA does not approve dietary supplements for safety and effectiveness before sale. A policosanol supplement listing therefore does not establish FDA approval of its benefits. Product-specific compliance and the rules in other markets require separate checks.

European assessment — checked 14 October 20266

EFSA concluded in its 2011 assessment that the submitted evidence did not establish the specified LDL- and HDL-cholesterol claims for sugarcane policosanols. This historical scientific opinion is not a general sales ban or a determination of every product’s current legal status.

09

How it compares

Why the lipid evidence is mixed3

A 2018 meta-analysis of 22 trials found favorable pooled lipid changes, but results varied considerably. Cuban studies showed larger effects than studies elsewhere, and dose-response was inconsistent. A favorable pooled average therefore does not predict a reliable result from an individual product.

A negative trial using Cuban material1

The German JAMA trial randomized 143 adults with elevated lipids. It used Cuban sugarcane policosanol and found no lipid benefit beyond placebo. Differences in wax source alone cannot explain every failed replication.

A newer positive result8

A 2023 randomized Japanese trial reported improved HDL-related and other blood markers after 12 weeks with Cuban policosanol. Authors included Raydel Research Institute researchers. This adds a favorable result outside Cuba, but remains a marker study rather than evidence of cognitive or long-term clinical benefit.

Octacosanol percentage is not total policosanol purity6

Octacosanol is one alcohol within the mixture. For an illustrative 20 mg serving of total policosanol containing 30% octacosanol, the octacosanol amount is 6 mg. That percentage does not mean the entire mixture is only 30% policosanol. Confirm what each percentage describes before comparing labels.

10

Practical buying and quality notes

  • Some listed powder variants have conflicting package sizes, and capsule entries may show different prices for the same count. Confirm the selected size and checkout price with the retailer. Compare cost per declared policosanol amount only after the net weight and serving content agree; displayed per-gram prices may be unreliable.9
  • Check wax source, total policosanol per serving and the constituent breakdown. A certificate of analysis should match the product and batch. Quality testing can support identity and content; it does not establish the clinical effectiveness of that mixture.9
11

FAQ

Can lipid-marker results justify replacing prescribed care?

9

No. A blood-marker study does not establish equivalent clinical outcomes. NIH advises obtaining professional approval before using a supplement in place of, or alongside, prescribed medicines.

Should policosanol be cycled?

2

The cited studies used defined research courses; they did not validate an on/off cycling schedule. Ending a study is not evidence that cycling improves safety or effectiveness.

12

References

  1. Berthold HK, Unverdorben S, Degenhardt R, Bulitta M, Gouni-Berthold I. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. JAMA. 2006.
  2. Dulin MF, Hatcher LF, Sasser HC, Barringer TA. Policosanol is ineffective in the treatment of hypercholesterolemia: a randomized controlled trial. Am J Clin Nutr. 2006.
  3. Gong J, Qin X, Yuan F, Hu M, Chen G, et al. Efficacy and safety of sugarcane policosanol on dyslipidemia: A meta-analysis of randomized controlled trials. Mol Nutr Food Res. 2018.
  4. Arruzazabala ML, Molina V, Mas R, Fernandez L, Carbajal D, et al. Antiplatelet effects of policosanol (20 and 40 mg/day) in healthy volunteers and dyslipidaemic patients. Clin Exp Pharmacol Physiol. 2002.
  5. U.S. Food and Drug Administration. FDA 101: Dietary Supplements.
  6. EFSA NDA Panel. Scientific opinion on sugarcane policosanols and blood LDL- and HDL-cholesterol claims. EFSA Journal. 2011;9(6):2255.
  7. Arruzazabala ML, Valdes S, Mas R, Carbajal D, Fernandez L. Comparative study of policosanol, aspirin and their combination on platelet aggregation. Pharmacol Res. 1997;36(4):293-297.
  8. Cho KH, Nam HS, Baek SH, et al. Cuban policosanol, blood pressure and lipoproteins in healthy Japanese adults: randomized trial. Int J Mol Sci. 2023;24(6):5185.
  9. NIH Office of Dietary Supplements. Dietary Supplements: What You Need to Know.
Note

This page is informational and summarizes available evidence. It is not medical advice, a recommendation, or a substitute for guidance from a qualified clinician.